Depressive Symptoms, Parkinson's Disease
Conditions
Keywords
Rasagiline, Depressive Symptoms, Cognition
Brief summary
The primary endpoint for this study is the clinical response after 12 weeks of treatment, defined as a change in total score from baseline depressive symptoms as measured by the Beck Depression Inventory-Amended (BDI-IA) total score.
Detailed description
ACCORDO is a multicentre, randomised, double-blind, and placebo-controlled study conducted in 12 Italian centres. Subjects are screened by means of the BDI-IA (cut-off 15) and randomised to treatment with rasagiline or placebo for 12 weeks. Subjects have to be on stable treatment with dopaminergic agents at least 4 weeks before baseline, and maintained so during the course of the study. The primary objective is to evaluate whether rasagiline compared to placebo improves depressive symptoms as evaluated by the BDI-IA total score.
Interventions
DRUGRasagiline
1 mg/day for 12 weeks; orally
DRUGPlacebo
Once daily for 12 weeks; orally
Sponsors
Teva Branded Pharmaceutical Products R&D, Inc.
Lundbeck Italia S.p.A.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Outpatient, male or female aged \>=40 and \<80 years. The subject has a diagnosis of idiopathic Parkinson's Disease (PD) according to the United Kingdom Parkinson's Disease Society brain bank diagnostic criteria for PD for the clinical diagnosis of PD. * Depressive symptoms with a minimum severity of \>=15 using the BDI-IA. * Hoehn and Yahr stage I-III. * Under stable (4 weeks prior to baseline) dopaminergic treatment without significant motor complication such as on-off phenomena and/or dyskinesia. * The subject and/or legal representative and/or impartial witness is/are able to read and understand the Subject Information Sheet. * The subject and/or legal representative has/have signed the Informed Consent Form (ICF) and if relevant the impartial witness has co-signed the ICF. * If female, must: agree not to try to become pregnant during the study (female patients of childbearing potential will take pregnancy test, using a urine stick), AND use adequate contraception (adequate contraception is defined as oral/systemic contraception, intrauterine device, diaphragm in combination with spermicidal, or condom for male partner in combination with spermicidal), OR have been menopausal for at least 24 months prior to baseline, (OR) have been surgically sterilised prior to baseline, OR have had a hysterectomy prior to baseline.
Exclusion criteria
A subject, who meets one or more of the following criteria at the Baseline Visit, is not eligible for inclusion in this study: * Motor complications such as wearing off and on-off phenomena. * Mini-Mental State Examination (MMSE) \<26, corrected score. * Diagnosis of current or history of major depressive episode according to DSM-IV-TR® criteria within 1 year before recruitment into the study. * Presence of any other neurodegenerative disorder other than PD, based on judgement of investigator. * Psychotic symptoms, e.g. hallucination and delirium (determined by clinical evaluation). * Presence of any unstable or untreated systemic disorder such as diabetes, cardiac failure, or renal failure. * Use of any prohibited concomitant medication according to the timelines provided in Appendix II. * Patient who have undergone Deep Brain Stimulation surgery. * Current treatment with antidepressants or history of treatment with antidepressants less than 1 month prior to randomisation. * Current treatment or history of treatment less than 1 month prior to randomisation, with antipsychotics, cholinesterase inhibitors, memantine, amantadine, or anticholinergics. * Current treatment with selegiline or history of treatment with selegiline less than 90 days prior to randomisation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Change from baseline in BDI-IA total score | 12 weeks |
Secondary
| Measure | Time frame |
|---|---|
| Evaluate if rasagiline compared to placebo improves cognitive function, over a treatment period of 12 weeks in idiopathic Parkinson´s Disease, using a formal neuropsychiatric cognitive test battery; quality of life (PDQ 39); apathy; ADL, motor function | 12 weeks |
| Change in quality of life using the PDQ-39 scale | 12 weeks |
| Change in apathy using the Apathy Scale | 12 weeks |
| Change in ADL and motor function using UPDRS scales part II and III, respectively | 12 weeks |
Countries
Italy
Outcome results
None listed